Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2719125 | 0.90 | TP53 (0.38) | TP53TSHRMAPTHPGDMEN1 | |
| SCHEMBL2719714 | 0.83 | TDP1 (0.34) | TP53TSHRMAPTHPGDMEN1 | |
| SCHEMBL2718545 | 0.83 | TDP1 (0.34) | TP53TSHRMAPTHPGDMEN1 | |
| SCHEMBL2827501 | 0.82 | TP53 (0.36) | TP53TSHRMAPTHPGDMEN1 | |
| SCHEMBL4191902 | 0.81 | ALDH1A1 (0.43) | TP53TSHRMAPTHPGDMEN1 | |
| SCHEMBL4207484 | 0.80 | ALDH1A1 (0.39) | TP53TSHRMAPTHPGDMEN1 | |
| SCHEMBL4202582 | 0.80 | TP53 (0.36) | TP53TSHRMAPTHPGDMEN1 | |
| SCHEMBL2720601 | 0.78 | ALDH1A1 (0.34) | TP53TSHRMAPTHPGDMEN1 | |
| SCHEMBL4203672 | 0.78 | TP53 (0.39) | TP53TSHRMAPTHPGDMEN1 | |
| SCHEMBL4195134 | 0.78 | ALDH1A1 (0.40) | TP53TSHRMAPTHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054669-A1 | Process For Producing Epoxy Compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090018355-A1 | Process for Crystallizing an Epoxy Compound | SUMITOMO CHEMICAL COMPANY, LTD. | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018355-A1 | Process for Crystallizing an Epoxy Compound | PTGER1, NR5A1, TCP1 | TP53 3527/4885TSHR 1136/4885MAPT 2433/4885 |
| US-20090054669-A1 | Process For Producing Epoxy Compound | RER1, AR, CYP1A1 | TP53 4049/4885TSHR 2772/4885MAPT 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.